Search results for " INDUCTION"

showing 10 items of 526 documents

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (R…

2015

Background: VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma following first-line therapy with sorafenib. Methods: In this randomised, placebo-controlled, double-blind, multicentre, phase 3 trial (REACH), patients were enrolled from 154 centres in 27 countries. Eligible patients were aged 18 years or older, had hepatocellular carcinoma with Barcelona Clinic Liver Cancer stage C disease or stage B disease that was refractory or not amenable to locoregional therapy…

MaleTime FactorsKaplan-Meier EstimateGastroenterologyLiver diseaseClinical endpoint610 Medicine & healthramucirumab sorafenib HCCAged 80 and overeducation.field_of_studyLiver NeoplasmsRemission InductionAntibodies MonoclonalMiddle AgedSorafenibTreatment OutcomeOncologyLiver NeoplasmHepatocellular carcinomaFemaleSurvival AnalysiHumanmedicine.drugAdultNiacinamidePhenylurea CompoundSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorPopulationAntibodies Monoclonal HumanizedPlaceboDisease-Free SurvivalDrug Administration ScheduleFollow-Up StudieRamucirumabDouble-Blind MethodInternal medicineConfidence IntervalsmedicineCarcinomaHumanseducationProportional Hazards ModelsAgedDose-Response Relationship Drugbusiness.industryPhenylurea CompoundsPatient Selectionmedicine.diseaseSurvival Analysisdigestive system diseasesSurgeryProportional Hazards ModelbusinessConfidence IntervalFollow-Up StudiesThe Lancet Oncology
researchProduct

Vitamin A Deficiency Increases Protein Catabolism and Induces Urea Cycle Enzymes in Rats

2010

Chronic vitamin A deficiency induces a substantial delay in the rates of weight and height gain in both humans and experimental animals. This effect has been associated with an impaired nutrient metabolism and loss of body protein. Therefore, we analyzed the effect of vitamin A deficiency on endogenous proteolysis and nitrogen metabolism and its reversibility with all-trans retinoic acid (RA). Male weanling rats, housed in pairs, were pair-fed a vitamin A-deficient (VAD) or control diet until they were 60 d old. A group of deficient rats were further treated with daily intraperitoneal injections of all-trans RA for 10 d. Final body and tissue (i.e. liver and heart) weights were significantl…

MaleVitaminmedicine.medical_specialtyNitrogenMedicine (miscellaneous)TretinoinBiologyAntioxidantsRetinoidschemistry.chemical_compoundInternal medicinemedicineAnimalsUreaMuscle SkeletalTriglyceridesNutrition and DieteticsVitamin A DeficiencyCatabolismRetinolProtein turnoverMethylhistidinesmedicine.diseaseRatsVitamin A deficiencyProtein catabolismEndocrinologyLiverchemistryEnzyme InductionUrea cycleLipid PeroxidationEnergy sourceThe Journal of Nutrition
researchProduct

Induction of cytochrome P450 and/or detoxication enzymes by various extracts or rosemary: description of specific patterns

2001

The ability of rosemary to modulate cytochrome P450 (CYP) and detoxication enzymes in rat liver was evaluated by comparing the effects of dried leaves and leaf extracts with different chemical compositions: essential oil (EO) containing monoterpenes, a dichloromethane extract (DCME) containing phenolic diterpenes and a water-soluble extract (WSE) containing phenolic compounds such as rosmarinic acid and flavonoids. Chemical analyses were done in order to characterize the composition of extracts. Male Wistar rats received the leaves or extracts of rosemary in their diet at 0.5% (w/w) for 2 weeks. The effects of such treatments were evaluated for CYP (1A, 2B, 2E1), glutathione S-transferase (…

Male[SDV]Life Sciences [q-bio]ReductaseToxicologychemistry.chemical_compoundCytosol0302 clinical medicineCytochrome P-450 Enzyme System[SDV.IDA]Life Sciences [q-bio]/Food engineeringCYTOCHROME P 450AnticarcinogenComputingMilieux_MISCELLANEOUSchemistry.chemical_classificationGLUTATHIONE S-TRANSFERASE0303 health sciencesbiologyReverse Transcriptase Polymerase Chain ReactionChemistryRosmarinic acidOrgan SizeGeneral Medicine[SDV.IDA] Life Sciences [q-bio]/Food engineeringSpecific Pathogen-Free Organisms[SDV] Life Sciences [q-bio]LiverBiochemistryEnzyme Induction030220 oncology & carcinogenesisMicrosomes Liver[SPI.GPROC] Engineering Sciences [physics]/Chemical and Process EngineeringImmunoblottingChemopreventiondigestive system03 medical and health sciencesAnimals[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringRNA MessengerRats Wistar030304 developmental biologyLamiaceaePlant ExtractsBody WeightROMARINCytochrome P450GlutathioneUDP-GLUCURONOSYLTRANSFERASENAD(P)H Dehydrogenase (Quinone)RatsEnzymeMicrosomebiology.proteinRATFood Science
researchProduct

Rat pineal arylalkylamine-N-acetyltransferase: cyclic AMP inducibility of its gene depends on prior entrained photoperiod.

2003

The nocturnal biosynthesis of melatonin in the rat pineal depends on strongly enhanced expression of the enzyme N-acetyltransferase [arylalkylamine N-acetyltransferase (AA-NAT); EC 2.3.1.87]. AA-NAT transcription is stimulated during darkness by adrenergic inputs to the pineal from the suprachiasmatic nucleus (SCN). Nocturnal activation of the AA-NAT promotor following stimulation of pinealocyte adrenoceptors involves cAMP-dependent stimulation of protein kinase A (PKA). The nocturnal rise in AA-NAT depends on the lighting conditions. As compared with light/dark (LD) 12:12, the delay between dark onset and the nocturnal rise in AA-NAT is shortened under long photoperiods and prolonged under…

Maleendocrine systemmedicine.medical_specialtyArylamine N-AcetyltransferasePhotoperiodStimulationBiologyPineal GlandGene Expression Regulation EnzymologicPinealocyteMelatoninRats Sprague-DawleyCellular and Molecular NeuroscienceNorepinephrineOrgan Culture TechniquesInternal medicineReceptors Adrenergic betamedicineCyclic AMPAnimalsProtein kinase AMolecular BiologyMelatoninphotoperiodismSuprachiasmatic nucleusfungiAdrenergic beta-AgonistsDarknessCyclic AMP-Dependent Protein KinasesCircadian RhythmRatsbody regionsEndocrinologyEnzyme InductionDarknessArylalkylaminehormones hormone substitutes and hormone antagonistsPhotic Stimulationmedicine.drugSignal TransductionBrain research. Molecular brain research
researchProduct

TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic …

2009

TLRs represent the first line of defense against invading pathogens in the innate immune system. Certain cytokines are important mediators and essentially necessary to assure an appropriately regulated immune response. Recent data gave initial evidence that IL-1beta is one of the most relevant members of these regulating cytokines. We investigated the induction of IL-1beta production in monocytes and pDCs stimulated with ligands for TLR7 and TLR8 and with antiphospholipid antibodies (aPL). Using human monocytes and pDCs for stimulation with specific TLR7 and TLR8 ligands such as resiquimod (R848) and single stranded RNA (RNA42) as well as with a human monoclonal aPL HL5B resulted in a speci…

Malemedicine.drug_classImmunologyInterleukin-1betaCaspase 1Enzyme-Linked Immunosorbent AssayCell SeparationBiologyRegulatory Sequences Nucleic AcidMonoclonal antibodyLigandsMonocytesProinflammatory cytokinechemistry.chemical_compoundImmune systemmedicineImmunology and AllergyHumansInnate immune systemCaspase 1ImidazolesHematologyTLR7Dendritic CellsTLR8Oligonucleotides AntisenseAntiphospholipid SyndromeFlow CytometrychemistryToll-Like Receptor 7Toll-Like Receptor 8Enzyme InductionImmunologyAntibodies AntiphospholipidRNAFemaleResiquimodImmunobiology
researchProduct

Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study.

2008

Abstract Background Infliximab (IFX), the chimeric anti TNFalpha antibody, an established treatment for Crohn's disease in adults and in children, is used less frequently in ulcerative colitis (UC). Aim of the study To report the clinical course of pediatric patients with active UC receiving IFX. Patients and methods Charts of 22 patients were reviewed (13 male, 9 female): 4 with a severe UC attack refractory to systemic corticosteroids (CS); 18 with a protracted course, of which 16 CS-dependent and 2 CS-resistant. The baseline therapeutic program consisted of 3 consecutive intravenous infusions (0, 2, 6 weeks) of IFX (5 mg/kg), followed by a retreatment schedule (infusion every 8 weeks); a…

Malemedicine.medical_specialtyAdolescentmedicine.medical_treatmentPediatric ulcerative colitisAzathioprineGastroenterologyRefractoryInternal medicineAzathioprinemedicineHumansColitisChildColectomyRetrospective StudiesSalvage TherapyHepatologybusiness.industryRemission InductionGastroenterologyAntibodies Monoclonalmedicine.diseaseUlcerative colitisInfliximabInfliximabMulticenter studyItalyColitis UlcerativeDrug Therapy CombinationFemalebusinessImmunosuppressive Agentsmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Late-onset myasthenia gravis - CTLA4(low) genotype association and low-for-age thymic output of naïve T cells.

2014

Abstract Late-onset myasthenia gravis (LOMG) has become the largest MG subgroup, but the underlying pathogenetic mechanisms remain mysterious. Among the few etiological clues are the almost unique serologic parallels between LOMG and thymoma-associated MG (TAMG), notably autoantibodies against acetylcholine receptors, titin, ryanodine receptor, type I interferons or IL-12. This is why we checked LOMG patients for two further peculiar features of TAMG – its associations with the CTLA4 high/gain-of-function  +49A/A genotype and with increased thymic export of naive T cells into the blood, possibly after defective negative selection in AIRE-deficient thymomas. We analyzed genomic DNA from 116 …

Malemedicine.medical_specialtyGenotypeThymomaT-LymphocytesImmunologyDNA Mutational AnalysisRecent Thymic EmigrantLate onsetCell CountThymus GlandBiologyPeripheral blood mononuclear cellWhite PeopleGene FrequencyInternal medicineGenotypeMyasthenia GravismedicineImmune ToleranceImmunology and AllergyHumansCTLA-4 AntigenGenetic Predisposition to DiseaseGenetic Association StudiesAgedPeripheral tolerance inductionAged 80 and overPolymorphism GeneticThymocytesT-cell receptor excision circlesAutoantibodyCell DifferentiationThymus NeoplasmsMiddle Agedmedicine.diseaseMyasthenia gravisEndocrinologyImmunologyFemaleJournal of autoimmunity
researchProduct

Selective induction of bilirbuin UDP-glucuronosyl-transferase by perfluorodecanoic acid

1991

Differential effects of perfluorodecanoic acid (PFDA) on rat liver UDP-glucuronosyltransferase isoenzymes have been observed after a single i.p. administration of the compound to young male Sprague-Dawley rats. (1) Bilirubin glucuronidation was induced 2-fold. The induced state was stable for at least 3 weeks. (2) Glucuronidation of 1-naphthol, morphine and testosterone was decreased to half of the control values. These decreases were maximal after 12 days but all three activities returned to normal levels after 3 weeks. (3) Immunoblotting experiments indicated that the differential effects of PFDA on UDP-glucuronosyltransferase activities were due to modulation of enzyme protein concentrat…

Malemedicine.medical_specialtyGlucuronosyltransferaseBilirubinImmunoblottingGlucuronidationToxicologyIsozymechemistry.chemical_compoundInternal medicinemedicineAnimalsInducerGlucuronosyltransferaseEnzyme inducerTestosteroneFluorocarbonsDose-Response Relationship DrugbiologyRats Inbred StrainsGeneral MedicineRatsIsoenzymesEndocrinologychemistryEnzyme InductionToxicitybiology.proteinDecanoic AcidsChemico-Biological Interactions
researchProduct

Efficacy and safety of yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for auto…

2007

A prospective, multicenter, nonrandomized phase 2 trial was conducted to evaluate the efficacy and safety of a single dose of yttrium-90 (90Y) ibritumomab tiuxetan in elderly patients in first relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) ineligible for stem-cell transplantation. Patients had been previously treated with chemotherapy (group A, n = 76) or chemotherapy plus rituximab (group B, n = 28). Patients in group A were further divided into patients in whom induction therapy had failed (stratum AI, n = 33) and patients who had relapsed after achieving complete response (CR; stratum AII, n = 43). The overall response rate (ORR) was 52% and 53% in strata AI and AII…

Malemedicine.medical_specialtyLymphoma B-Cellmedicine.medical_treatmentImmunologyIbritumomab tiuxetanSalvage therapyAuthor Keywords:RadioimmunotherapyBiochemistryGastroenterologyAntibodies Monoclonal Murine-DerivedTRIAL Author InformationAutologous stem-cell transplantationRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineRefractory Diffuse Large B-Cell LymphomaHumansYttrium RadioisotopesY-90-ibritumomab tiuxetanHematologic toxicity KeyWords Plus:B-CELL LYMPHOMAAuthor Keywords:Radioimmunotherapy; Y-90-ibritumomab tiuxetan; Hematologic toxicity KeyWords Plus:B-CELL LYMPHOMA; LOW-GRADE; RADIOIMMUNOTHERAPY; INDOLENT; TRIAL Author InformationAgedCerebral HemorrhageAged 80 and overSalvage TherapyChemotherapybusiness.industryRemission InductionAntibodies MonoclonalCell BiologyHematologyRADIOIMMUNOTHERAPYINDOLENTmedicine.diseaseSurvival AnalysisLOW-GRADESurgeryTransplantationRituximabFemaleLymphoma Large B-Cell DiffusebusinessRituximabDiffuse large B-cell lymphomamedicine.drug
researchProduct

Remission phase in children diagnosed with type 1 diabetes in years 2012 to 2013 in Silesia, Poland: An observational study

2018

Background/objective The study aimed to analyze the frequency of partial remission (PR) and its association with chosen clinical and laboratory factors among pediatric patients with newly diagnosed type 1 diabetes (T1D). The long-term effect of PR on chosen parameters was also investigated. Methods In 194 patients (95 girls) aged 8.1 ± 4.3 years, we analyzed data at T1D onset: glycemia, pH, C-peptide, antibodies, weight, and concomitant autoimmune diseases. Anthropometric parameters, daily insulin requirement (DIR), and HbA1c 2 and 4 years after T1D diagnosis were also analyzed. We determined PR based on HbA1c and DIR measurements at least every 3 months. Results PR occurred in 59% of patie…

Malemedicine.medical_specialtyMultivariate analysisAdolescentEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismGastroenterologyDiabetic Ketoacidosis03 medical and health sciences0302 clinical medicineInternal medicineRemission phaseInternal MedicinemedicineHumans030212 general & internal medicineAge of OnsetChildGlycated HemoglobinType 1 diabetesbusiness.industryInsulinRemission InductionAge Factorsmedicine.diseaseKetoacidosisDiabetes Mellitus Type 1Child PreschoolConcomitantPediatrics Perinatology and Child HealthFemaleObservational studyPolandbusinessBody mass indexPediatric Diabetes
researchProduct